Explorative Trial to Investigate the Safety and Clinical Effects of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) Following Their Intrathecal and Intravenous Administration in Severe Cases of Multiple Sclerosis (MS) is a PHASE1 clinical asset sponsored by Hadassah Medical Organization in Multiple Sclerosis. SEO and diligence focus: Injection of autologous bone marrow derived mesenchymal stem cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.